Clinical Review

Pediatric Molluscum: An Update

Author and Disclosure Information

Molluscum contagiosum virus (MCV) is a poxvirus that causes infection in humans that is limited to the cutis and subcutaneous levels of the skin. The virus is transmitted from close associates in settings such as pools, day care, and bathtubs. Pediatric molluscum is common in school-aged children and resolves spontaneously in healthy children. Widespread lesions, complicated by comorbid dermatitis, are expected in children with atopic dermatitis (AD); however, even children without AD can develop dermatitis or signs of inflammation or pruritus. Molluscum is the great mimicker in pediatric dermatology; the morphology of the lesions and overlying rash can make molluscum look polymorphous and similar to other skin illnesses. This article addresses the issue of transmission, course of disease, comorbidities, and therapeutic options, including the gold standard—nonintervention. The decision to intervene is a joint decision among children, parents/guardians, and the practitioner. The first priority should be reduction of symptoms, followed by reduction of spread and then disease remission.

Practice Points

  • Molluscum appears as pearly papules with a central dell (ie, umbilicated).
  • Caused by a poxvirus, the disease is very contagious and transferred via skin-to-skin contact or fomites.
  • One-third of children with molluscum will develop symptoms of local erythema, swelling, or pruritus.
  • Diagnosis usually is clinical.
  • Children are primarily managed through observation; however, cantharidin, cryotherapy, or curettage can be used for symptomatic or cosmetically concerning lesions.


 

References

Molluscum contagiosum virus (MCV) infection causes the cutaneous lesions we call molluscum. Molluscum has become common in the last 30 years. Deciding the best course of therapy requires some fundamental understanding about how MCV relates to the following factors: epidemiology, childhood immunity and vaccination, clinical features, comorbidities, and quality of life. Treatment depends on many factors, including presence or absence of atopic dermatitis (AD) and/or pruritus, other symptoms, cosmetic location, and the child’s concern about the lesions. Therapeutics include destructive and immunologic therapies, the latter geared toward increasing immune response.

Epidemiology

Molluscum contagiosum virus is the solo member of the Molluscipoxvirus genus. Infection with MCV causes benign growth or tumors in the skin (ie, molluscum). The infection is slow to clear because the virus reduces the host’s immunity.1,2 Molluscum contagiosum virus is a double-stranded DNA virus that affects keratinocytes and genetically carries the tools for its own replication (ie, DNA-dependent RNA polymerase). The virus has a few subtypes—I/Ia, II, III, and IV—with MCV-I predominating in children and healthy humans and MCV-II in patients with human immunodeficiency virus.1,2 Typing is experimental and is not standardly performed in clinical practice. Molluscum contagiosum virus produces a variety of factors that block the host’s immune response, prolonging infection and preventing erythema and inflammatory response.3

Molluscum contagiosum virus is transmitted through skin-to-skin contact and fomites, including shared towels, bathtubs, spas, bath sponges, and pool equipment.2,4,5 Transmission from household contact and bathing together has been noted in pediatric patients with MCV. Based on the data it can be posited that the lesions are softer when wet and more readily release viral particles or fomites, and fomites may be left on surfaces, especially when a child is wet.6,7 Propensity for infection occurs in patients with AD and in immunosuppressed hosts, including children with human immunodeficiency virus and iatrogenic immunosuppression caused by chemotherapy.1,2,8 Contact sports can increase the risk of transmission, and outbreaks have occurred in pools,5,9 day-care facilities,10 and sports settings.11 Cases of congenital and vertically transmitted molluscum have been documented.12,13 Sexual transmission of MCV may be seen in adolescents who are sexually active. Although child-to-child transmission can occur in the groin area from shared equipment, transmission via sexual abuse also is possible.14 Bargman15 has mentioned the isolated genital location and lack of contact with other infected children as concerning features. Latency of new lesion appearance is anywhere from 1 to 50 days from the date of inoculation; therefore, new lesions are possible and expected even after therapy has been effective in eradicating visible lesions.10 Although clearance has been reported in 6 to 12 months, one pediatric study demonstrated 70% clearance by 1.5 years, suggesting the disease often is more prolonged.16 One-third of children will experience signs of inflammation, such as pruritus and/or erythema. Rare side effects include bacterial superinfection and hypersensitivity.2

One Dutch study from 1994, the largest database survey of children to date, cited a 17% cumulative incidence of molluscum in children by reviewing the data from 103 general practices.17 In a survey and review of molluscum by Braue et al,18 annual rates in populations vary but seem to maximize at approximately 6% to 7%. Sturt et al19 reviewed the prevalence in the indigenous West Sepik section of New Guinea and noted annual incidence rates of 6% in children younger than 10 years (range, 1.8%–10.9%). Epidemics occur and can produce large numbers of cases in a short time period.18 The cumulative prevalence in early childhood may be as high as 22%, as Sturt et al19 observed in children younger than 10 years.

Rising incidence and therefore rising lifetime prevalence appear to have been an issue in the last few decades. Data from the Indian Health Service have demonstrated increases in MCV in Native American children between 2001 and 2005.20 In adults, the data support a steady increase of molluscum from 1988-2007, with a 3-fold increase from 1988-1997 to 1998-2007 in a Spanish study.21 Better population-based data are needed.

Pages

Recommended Reading

One-year data support dupilumab’s efficacy and safety in adolescents with AD
MDedge Dermatology
Tape strips useful to identify biomarkers in skin of young children with atopic dermatitis
MDedge Dermatology
Pruritic, pink to violaceous, scaly papules
MDedge Dermatology
Spotting immunodeficiency in the pediatric dermatology clinic
MDedge Dermatology
Atopic Dermatitis Affects Sleep and Work Productivity
MDedge Dermatology
Flu vaccine: Larger impact on influenza burden than you thought?
MDedge Dermatology
PASI-75 with ixekizumab approaches 90% in pediatric psoriasis study
MDedge Dermatology
Psoriasis risk rises with TNF inhibitor use in children with inflammatory disorders
MDedge Dermatology
Neonatal Consultations: Vascular Lumps, Bumps, and Tumors in the Neonate
MDedge Dermatology
Patch Testing in Children: Not Just Little Adults
MDedge Dermatology